Cipher Pharmaceuticals Secures pCPA Agreement to Expand Public Access to Epuris Across Canada
Cipher Pharmaceuticals has completed negotiations with the pan-Canadian Pharmaceutical Alliance, securing a Letter of Intent for Epuris (isotretinoin). The agreement represents a significant step toward expanding public drug plan coverage and improving patient access to severe acne treatment across Canada.
Drug Formularies | 09/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy